The trial, MM-002, had been a randomized open-label Stage II study evaluating pomalidomide plus low-dose dexamethasone versus pomalidomide alone in relapsed and refractory several myeloma patients. Pomalidomide, with or without low-dose dexamethasone, was presented with in 28-day cycles: pomalidomide 4 mg once daily with days 1-21 every 28 days, together with low-dose dexamethasone (40 mg) weekly.

Results presented were based on investigator-assessed responses for the intent-to-treat population. A total of 221 patients were enrolled in the study, together with 191 patients were available for response. The study showed that using 191 evaluable patients, partial response (PUBLIC REALTIONS) or better was affecting 34% of patients treated with pomalidomide plus low-dose dexamethasone compared with 13% of patients taken care of with pomalidomide alone.

Objective responses (insignificant response or better) were affecting 45% of patients treated with pomalidomide plus low-dose dexamethasone compared with 29% in the pomalidomide-only tricep / bicep. Typical progression-free survival, the primary end point of the study, had been 4. 7 months inside pomalidomide plus low-dose dexamethasone arm weighed against 2. 7 months in the pomalidomide- alone arm. Median duration of response (DOR) was 7. 9 months in the pomalidomide plus low-dose dexamethasone arm compared with 8. 5 months with pomalidomide alone, and median overall survival was 16. 9 months compared using 14 months, respectively. Similar results were observed in all subsets of patients, including patients refractory to lenalidomide and patients refractory to both lenalidomide and bortezomib. Results from the independent adjudication were similar.

People in both arms of the study had been heavily treated just before enrollment, with a typical of 5 (range, 2 to 13) previously therapies. More than 74% and 76% of patients in the pomalidomide plus low-dose dexamethasone upper extremity and pomalidomide alone tricep / bicep, respectively, had undergone autologous root cell transplantation.

Discontinuation rate due to adverse events was 6% in the pomalidomide plus low-dose dexamethasone arm, compared with 12% inside pomalidomide alone arm. The commonest grade 3 or 4 adverse events in the pomalidomide plus low-dose dexamethasone tricep / bicep versus pomalidomide alone have been neutropenia (38% together with 45%, respectively), anemia (21%, 17%), pneumonia (19%, 8%), thrombocytopenia (19%, 21%), together with fatigue (10%, 8%).

A lot of these data are from a great investigational study. Pomalidomide is not an approved product for any indication.

Patients with MM who have progressed after multiple innovative agents have limited treatment options. Pomalidomide at doses associated with 2 or 4 mg/day provides demonstrated excellent activity. People opened two sequential phase II trials while using Pom/dex regimen at differing doses to check the efficacy of this regimen in patients who have failed both lenalidomide and bortezomib. Pomalidomide was provided orally 2 mg or even 4 mg daily with dexamethasone 40 mg weekly. 35 patients were enrolled in each cohort. Tested responses (>MR) inside 2 mg cohort contains VGPR in 5 (14%), PUBLIC REALTIONS in 4 (11%), MR in 8 (23%) for an overall response rate of 49%. Inside 4 mg cohort tested responses (>MR) contains CR in 1 (3%), VGPR with 3 (9%), PUBLIC REALTIONS in 6 (17%), MR with 5 (14%) for an overall response rate with 43%. Overall survival at a few months is 78% (95%CI: 65-94) and 67% (95%CI: 52-86) in the 2 and 4 mg cohort respectively. Myelosuppression was the most common toxicity. This non-randomized data has revealed no advantage for 4 mg in the 2 mg daily.

We announced that OstarineOstarine inhibition,Pomalidomide,Sorafenib inhibitor drug increased lean mass and leg press strength in a head to head study evaluating Ostarine and another selective androgen receptor modulator (SARM), MK-3984, within postmenopausal women. The information were presented at the 2010 Annual Meeting with the Endocrine Society. Ostarine, for the relief cancer induced muscle losing (cancer cachexia).

"This is the next Ostarine clinical study that measured lean mass and physical performance endpoints, together with Ostarine has consistently demonstrated enable you to increase muscle mass and strength, " said Mitchell S. Steiner"We also continue being pleased with Ostarine’s safety profile. "

The 12 week, randomized clinical trial assessed Ostarine 3 mg and two doses of MK-3984 as compared to placebo in 88 postmenopausal women. Total lean body mass was measured by DEXA with baseline and 12 months, together with physical performance was evaluated at the same interval by bilateral lower leg press machine.

After 12 months of treatment, Ostarine 3 mg and MK-3984 significantly increased total lean mass. Compared to placebo, mean differences from baseline for lean body mass were observed with increases of 1. 54 kg (p value <0.001) for both Ostarine 3 mg and 50 mg of MK- 3984 and an increase of 1.74 kg (p value<0.001) for 125 mg of MK-3984. Increases in thigh muscle volume as measured by MRI for Ostarine and MK-3984 were noted as early as week 4 with the effect persisting through the end of the study. Ostarine 3 mg and MK-3984 treatment resulted in an increase in leg muscle strength. Mean leg muscle strength at 12 weeks for Ostarine 3 mg treated subjects increased by 22 pounds from baseline.

Ostarine 3 mg and MK-3984 were tissue selective. Treatment did not cause virilization in these women, as there was no change in sebaceous gland volume, rate of sebum excretion, or hair follicle gene expression. Moreover, Ostarine 3 mg and MK-3984 did not stimulate endometrial proliferation as measured by endometrial thickness. As for safety, seven subjects treated with MK-3984 were discontinued from the study due to elevations in liver enzymes greater than three times the upper limit of normal, whereas no clinically significant liver enzyme elevations occurred in subjects treated with Ostarine.

In summary, 12 week treatment with Ostarine 3 mg and MK-3984 had comparable efficacy on total lean body mass, muscle strength and tissue selectivity in postmenopausal women. Ostarine 3 mg was well tolerated with no clinically significant liver enzyme elevations.

We today presented additional results from the Ostarine™ Phase IIb study demonstrating an improvement in quality of life (fatigue and anorexia) in cancer patients with muscle wasting (cancer cachexia) who demonstrated improvement in functional performance as measured by stair climb. Ostarine is lead selective androgen receptor modulator (SARM) which the company is developing for the treatment of cancer cachexia. The quality of life results (abstract #9147) were presented at the 2010 American Society of Clinical Oncology Annual Meeting.

"In three clinical trials in more than 380 patients, including this Phase IIb clinical trial in patients with cancer cachexia, Ostarine has demonstrated the ability to build muscle mass and improve functional performance," said Mitchell S. Steiner "We are encouraged that Ostarine has the potential to make a difference in a cancer patient's quality of life as measured by FACIT fatigue and FAACT anorexia scales."

The 16 week study evaluated Ostarine 1 mg and 3 mg compared to placebo in 159 cancer patients with non-small cell lung cancer, colorectal cancer, breast cancer, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma with cancer cachexia. Ostarine treatment resulted in a statistically significant increase in lean body mass and improvement in physical performance as measured by stair climb time and power.

The growth of many soft tissue sarcomas is dependent on aberrant growth factor signaling, which promotes their proliferation and motility. With this in mind, we evaluated the effect of sorafenib, a receptor tyrosine kinase inhibitor, on cell growth and apoptosis in sarcoma cell lines of various histological subtypes. We found that sorafenib effectively inhibited cell proliferation in rhabdomyosarcoma, synovial sarcoma and Ewing’s sarcoma with IC50 values <5 µM. Sorafenib effectively induced growth arrest in rhabdomyosarcoma cells, which was concurrent with inhibition of Akt and Erk signaling. Studies of ligand-induced phosphorylation of Erk and Akt in rhabdomyosarcoma cells showed that insulin-like growth factor-1 is a potent activator, which can be blocked by treatment with sorafenib. In vivo sorafenib treatment of rhabdomyosarcoma xenografts had a significant inhibitory effect on tumor growth, which was associated with inhibited vascularization and enhanced necrosis in the adjacent tumor stroma. Our results demonstrate that in vitro and in vivo growth of rhabdomyosarcoma can be suppressed by treatment with sorafenib, and suggests the possibilities of using sorafenib as a potential adjuvant therapy for the treatment of rhabdomyosarcoma.

Sorafenib is a multikinase inhibitor that blocks tumor cell proliferation and angiogenesis and is used for the treatment of advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and other solid tumors. Various dermatologic side effects have been reported, most notably a hand-foot-skin reaction (HFSR). This is a case of a sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. This patient also developed cutaneous squamous cell carcinoma and HFSR in association with sorafenib. To the authors' knowledge, a psoriasiform eruption due to sorafenib has not been reported in the literature and has important therapeutic implications.

Sorafenib (Nexavar, Bayer Healthcare Pharmaceuticals, Moontville, NJ-Onyx Pharmaceuticals, Emeryville, CA) is an orally available multikinase inhibitor (MKI) for the treatment of advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and other solid tumors. Sorafenib inhibits tumor cell proliferation, reduces tumor angiogenesis, and increases the rate of apoptosis in tumor models. It acts by inhibiting cell signaling via Raf-1 and B-Raf kinases; vascular endothelial growth factor receptors (VEGFR) 2 and 3; platelet-derived growth factor receptor [beta] (PDGFR[beta]); FMS-like tyrosine kinase 3 ; c-Kit protein; and RET receptor tyrosine kinases. Sorafenib monotherapy (400 mg twice daily) has been associated with various dermatologic toxicities, including hand-foot skin reaction (HFSR), xerosis, a non-specific exanthem, facial erythema, scalp dysethesia, alopecia, stomatitis and subungual splinter hemorrhages. Less commonly, keratoacanthomas (KAs), inflammation of actinic keratoses (AKs), and squamous cell carcinoma (SCC) have been reported.

The trial, MM-002, was a randomized open-label Phase II study evaluating pomalidomide plus low-dose dexamethasone versus pomalidomide alone in relapsed and refractory multiple myeloma patients. Pomalidomide, with or without low-dose dexamethasone, was given in 28-day cycles: pomalidomide 4 mg once daily on days 1-21 every 28 days, and low-dose dexamethasone (40 mg) weekly.

Results presented were based on investigator-assessed responses for the intent-to-treat population. A total of 221 patients were enrolled in the study, and 191 patients were available for response. The study showed that out of 191 evaluable patients, partial response (PR) or better was seen in 34% of patients treated with pomalidomide plus low-dose dexamethasone compared with 13% of patients treated with pomalidomide alone.

Objective responses (minor response or better) were observed in 45% of patients treated with pomalidomide plus low-dose dexamethasone compared with 29% in the pomalidomide-only arm. Median progression-free survival, the primary end point of the study, was 4.7 months in the pomalidomide plus low-dose dexamethasone arm compared with 2.7 months in the pomalidomide- alone arm. Median duration of response (DOR) was 7.9 months in the pomalidomide plus low-dose dexamethasone arm compared with 8.5 months with pomalidomide alone, and median overall survival was 16.9 months compared with 14 months, respectively. Similar results were observed in all subsets of patients, including patients refractory to lenalidomide and patients refractory to both lenalidomide and bortezomib. Results from the independent adjudication were similar.

Patients in both arms of the study had been heavily treated prior to enrollment, with a median of 5 (range, 2 to 13) prior therapies. More than 74% and 76% of patients in the pomalidomide plus low-dose dexamethasone arm and pomalidomide alone arm, respectively, had undergone autologous stem cell transplantation.

Discontinuation rate due to adverse events was 6% in the pomalidomide plus low-dose dexamethasone arm, compared with 12% in the pomalidomide alone arm. The most common grade 3 or 4 adverse events in the pomalidomide plus low-dose dexamethasone arm versus pomalidomide alone were neutropenia (38% and 45%, respectively), anemia (21%, 17%), pneumonia (19%, 8%), thrombocytopenia (19%, 21%), and fatigue (10%, 8%).

These data are from an investigational study. Pomalidomide is not an approved product for any indication.

Patients with MM who have progressed after multiple novel agents have limited treatment options. Pomalidomide at doses of 2 or 4 mg/day has demonstrated excellent activity. We opened two sequential phase II trials using the Pom/dex regimen at differing doses to study the efficacy of this regimen in patients who have failed both lenalidomide and bortezomib. Pomalidomide was given orally 2 mg or 4 mg daily with dexamethasone 40 mg weekly. 35 patients were enrolled in each cohort. Confirmed responses (> MR) in the 2 mg cohort contains VGPR in 5 (14%), PR in 4 (11%), MR in 8 (23%) for an overall response rate involving 49%. In the 4 mg cohort confirmed responses (>MR) consisted of CR in 1 (3%), VGPR within 3 (9%), PR in 6 (17%), MR with 5 (14%) for an overall response rate of 43%. Overall survival at a few months is 78% (95%CI: 65-94) together with 67% (95%CI: 52-86) inside 2 and 4 mg cohort respectively. Myelosuppression was the commonest toxicity. This non-randomized data recommends no advantage for 4 mg in the 2 mg daily.

People announced that Ostarine increased lean mass and leg press strength in a head to head study evaluating Ostarine together with another selective androgen receptor modulator (SARM), MK-3984, with postmenopausal women. The information were presented in the 2010 Annual Meeting with the Endocrine Society. Ostarine, for dealing with cancer induced muscle wasting (cancer cachexia).

"This is the lastly Ostarine clinical study that measured lean body mass and physical performance endpoints, and Ostarine has consistently demonstrated to be able to increase muscle mass together with strength, " said Mitchell S. Steiner"We also continue being pleased with Ostarine’s protection profile. "

The 12 week, randomized clinical trial evaluated Ostarine 3 mg together with two doses of MK-3984 in comparison to placebo in 88 postmenopausal females. Total lean body mass was measured by DEXA with baseline and 12 weeks, and physical performance was evaluated in the same interval by bilateral lower leg press machine.

After 12 months of treatment, Ostarine 3 mg together with MK-3984 significantly increased total lean mass. Compared to placebo, mean differences from baseline for lean mass were observed with increases of just one. 54 kg (k value<0. 001) for both Ostarine 3 mg and 50 mg of MK- 3984 and a small increase of 1. 74 kg (k value<0. 001) for 125 mg of MK-3984. Increases in thigh muscle volume as measured by MRI for Ostarine and MK-3984 were noted as soon as week 4 with the effect persisting through the end in the study. Ostarine 3 mg and MK-3984 treatment resulted in an increase in leg muscle strength. Mean lower leg muscle strength at 12 months for Ostarine 3 mg treated subjects increased by 25 pounds from baseline.

Ostarine 3 mg together with MK-3984 were tissue selective. Treatment did not purpose virilization in these a lot of women, as there was no change in sebaceous gland volume, rate of sebum excretion, or hair follicle gene expression. Moreover, Ostarine 3 mg and MK-3984 do not stimulate endometrial proliferation since measured by endometrial thickness. As to safety, seven subjects treated using MK-3984 were discontinued in the study due to elevations in liver enzymes greater than three times the upper limit of normal, whereas no clinically significant liver enzyme elevations occurred with subjects treated with Ostarine.

Summing up, 12 week treatment using Ostarine 3 mg and MK-3984 had comparable efficacy on total lean body mass, muscle strength and tissue selectivity in postmenopausal a lot of women. Ostarine 3 mg was well tolerated with no clinically significant liver enzyme elevations.

We today presented additional results from the Ostarine™ Phase IIb study demonstrating an improvement in quality of life (fatigue and anorexia) in cancer patients with muscle wasting (cancer cachexia) which demonstrated improvement in useful performance as measured by stair climb. Ostarine is lead selective androgen receptor modulator (SARM) the fact that company is developing for dealing cancer cachexia. The standard of living results (abstract #9147) were presented at the 2010 American Society involving Clinical Oncology Annual Meeting.

"In a few clinical trials in a lot more than 380 patients, including that Phase IIb clinical trial in patients with melanoma cachexia, Ostarine has demonstrated the ability to build muscle mass together with improve functional performance, " said Mitchell S. Steiner "We are encouraged that Ostarine has the potential to make a difference in a cancer patient's quality of life as measured by FACIT weakness and FAACT anorexia scales. "

The 16 week study evaluated Ostarine 1 mg and 3 mg compared to placebo in 159 tumor patients with non-small cellular lung cancer, colorectal melanoma, breast area cancer, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma with melanoma cachexia. Ostarine treatment resulted in a statistically significant increase in lean body mass and improvement in actual physical performance as measured just by stair climb time together with power.

The growth of numerous soft tissue sarcomas would depend on aberrant growth element signaling, which promotes their own proliferation and motility. That said, we evaluated the influence of sorafenib, some sort of receptor tyrosine kinase inhibitor, on cell growth and apoptosis in sarcoma cell lines of assorted histological subtypes. We identified that sorafenib effectively inhibited cell proliferation in rhabdomyosarcoma, synovial sarcoma together with Ewing’s sarcoma with IC50 ideals <5 µM. Sorafenib efficiently induced growth arrest in rhabdomyosarcoma cells, which had been concurrent with inhibition with Akt and Erk signaling. Reviews of ligand-induced phosphorylation of Erk and Akt within rhabdomyosarcoma cells showed that insulin-like growth factor-1 is a potent activator, which may be blocked by treatment with sorafenib. In vivo sorafenib treatment of rhabdomyosarcoma xenografts had a substantial inhibitory effect on cancer growth, which was linked to inhibited vascularization and enhanced necrosis inside adjacent tumor stroma. Our results demonstrate that in vitro and with vivo growth of rhabdomyosarcoma may be suppressed by treatment with sorafenib, and suggests the probability of using sorafenib as a potential adjuvant therapy for the relief rhabdomyosarcoma.

Sorafenib can be a multikinase inhibitor that blocks tumor cell proliferation and angiogenesis and it is used for dealing with advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and also other solid tumors. Various dermatologic side effects have been reported, most notably a hand-foot-skin reaction (HFSR). This can be a case of a sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. This patient also developed cutaneous squamous cell carcinoma and HFSR in colaboration with sorafenib. To the authors' knowledge, some sort of psoriasiform eruption due to sorafenib has not been reported in the literature and has important therapeutic implications.

Sorafenib (Nexavar, Bayer Medicine and health Pharmaceuticals, Moontville, NJ-Onyx Pharmaceuticals, Emeryville, CA) is a great orally available multikinase inhibitor (MKI) for the treatment of advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and also other solid tumors. Sorafenib inhibits tumor cell proliferation, lowers tumor angiogenesis, and increases the rate of apoptosis with tumor models. It functions by inhibiting cell signaling by way of Raf-1 and B-Raf kinases; vascular endothelial increase factor receptors (VEGFR) 2 and 3; platelet-derived growth factor receptor [beta] (PDGFR[beta]); FMS-like tyrosine kinase 3; c-Kit protein; and RET receptor tyrosine kinases. Sorafenib monotherapy (400 mg twice daily) has been associated with various dermatologic toxicities, which include hand-foot skin reaction (HFSR), xerosis, a non-specific exanthem, makeup erythema, scalp dysethesia, alopecia, stomatitis together with subungual splinter hemorrhages. Less commonly, keratoacanthomas (KAs), inflammation of actinic keratoses (AKs), and squamous cell carcinoma (SCC) have been reported.

Hi everyone! I'm just getting started on Xanga... Drop me a comment if you've got some ideas on what to do first - or just to say, "Hi!"